GIP/GLP-1/glucagon agonist
Retatrutide
Answer
Retatrutide is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. Highest trial phase: Phase 3 (20 phase 3 trials, 0 with posted results). It has 41 registered trials, 11 of them running.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
41 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 2 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 7 years · read 2026-10-03. 2026 is not complete. 8 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | Not on the register | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Retatrutide changes on the register. You confirm your address first.
ENFORCEMENT AND OFFICIAL ACTIONS
1 action by named authorities
Enforcement actions, board positions and payer rules that name Retatrutide, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.
| US-OHenforcement | Ohio Board of Pharmacy, 2026-04-16 During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: a. Retatrutide 10mg, 9 vials;State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraph 2(a) · quoted with the party redacted |
|---|
REGISTERED TRIALS
Newest 10 of 41 trials
| 2023-503658-11-00 | J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabete no status recorded · register updated 2026-09-29 |
|---|---|
| NCT06260722 | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Me running, but no longer enrolling · register updated 2026-09-28 |
| NCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain running, but no longer enrolling · register updated 2026-09-25 |
| NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcom running, but no longer enrolling · register updated 2026-09-24 |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) currently recruiting participants · register updated 2026-09-22 |
| 2025-522674-36-00 | N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participant no status recorded · register updated 2026-09-21 |
| NCT05929066 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed · register updated 2026-08-21 |
| 2024-511450-49-00 | J1I-MC-GZBP: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide no status recorded · register updated 2026-08-14 |
| NCT07629401 | Pre-approval Expanded Access of Retatrutide (LY3437943) available · register updated 2026-08-06 |
| NCT05882045 | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease completed · register updated 2026-07-30 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.